OliX PharmaceuticalsInc - Asset Resilience Ratio
OliX PharmaceuticalsInc (226950) has an Asset Resilience Ratio of 61.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 226950 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how OliX PharmaceuticalsInc's Asset Resilience Ratio has changed over time. See OliX PharmaceuticalsInc (226950) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down OliX PharmaceuticalsInc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OliX PharmaceuticalsInc (226950) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩114.17 Billion | 61.19% |
| Total Liquid Assets | ₩114.17 Billion | 61.19% |
Asset Resilience Insights
- Very High Liquidity: OliX PharmaceuticalsInc maintains exceptional liquid asset reserves at 61.19% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
OliX PharmaceuticalsInc Industry Peers by Asset Resilience Ratio
Compare OliX PharmaceuticalsInc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for OliX PharmaceuticalsInc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for OliX PharmaceuticalsInc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.96% | ₩8.52 Billion ≈ $5.78 Million |
₩71.25 Billion ≈ $48.28 Million |
-1.59pp |
| 2023-12-31 | 13.55% | ₩13.93 Billion ≈ $9.44 Million |
₩102.83 Billion ≈ $69.68 Million |
-33.09pp |
| 2022-12-31 | 46.64% | ₩61.87 Billion ≈ $41.93 Million |
₩132.65 Billion ≈ $89.90 Million |
-10.77pp |
| 2021-12-31 | 57.41% | ₩49.76 Billion ≈ $33.72 Million |
₩86.67 Billion ≈ $58.74 Million |
-29.27pp |
| 2020-12-31 | 86.68% | ₩68.11 Billion ≈ $46.16 Million |
₩78.58 Billion ≈ $53.25 Million |
+42.54pp |
| 2019-12-31 | 44.14% | ₩19.95 Billion ≈ $13.52 Million |
₩45.21 Billion ≈ $30.64 Million |
-7.65pp |
| 2018-12-31 | 51.79% | ₩28.81 Billion ≈ $19.53 Million |
₩55.64 Billion ≈ $37.70 Million |
-0.51pp |
| 2017-12-31 | 52.30% | ₩11.32 Billion ≈ $7.67 Million |
₩21.64 Billion ≈ $14.67 Million |
-10.30pp |
| 2016-12-31 | 62.60% | ₩9.48 Billion ≈ $6.43 Million |
₩15.15 Billion ≈ $10.27 Million |
-- |
About OliX PharmaceuticalsInc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more